Skip to main content
. Author manuscript; available in PMC: 2013 Oct 9.
Published in final edited form as: Ann Intern Med. 2011 Jul 19;155(2):69–79. doi: 10.7326/0003-4819-155-2-201107190-00002

Figure 2. Sensitivity analysis of number of relatives tested per proband.

Figure 2

Among tumor-testing strategies, IHC with BRAF testing had an incremental cost-effectiveness ratio <$50 000 per life-year gained when 3 relatives but not when 2 relatives were tested per proband. IHC = immunohistochemistry.